Oncology News | pharmaphorum

News

FDA grants fast review for AstraZeneca's Tagrisso in early-s...

The FDA has granted a fast review for AstraZeneca’s Tagrisso oncology drug in certain patients with early-stage lung cancer.

News

FDA kicks off review of second kidney cancer combo based on ...

Bristol-Myers Squibb could be mere months away from claiming a second US approval for an Opdivo-based combination immunotherapy that will help defend its first-line kidney cancer franchise.

News

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

News

"Tokyo, Japan - May 11, 2012: Pfizer building on May 11, 2012 in Tokyo. Pfizer is one of largest pharmaceutical companies worldwide with tremendous revenue $67.4 bn USD for 2011. It exists since 1849."

Ibrance trial failure dashes Pfizer’s growth hopes for the d...

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s

News

Shock as FDA rejects Mesoblast's Ryoncil in paediatric graft...

The FDA has rejected Mesoblast’s Ryoncil cell therapy for children with graft versus host disease, despite a recommendation to approve from a panel of expert advisers.

News

FDA approves BMS' Opdivo and Yervoy combination in first-lin...

Bristol-Myers Squibb’s immunotherapy combination of Opdivo and Yervoy has been approved in the US in a new indication for untreated mesothelioma, a rare but aggressive form of cancer that f

FDA grants fast review for AstraZeneca's Tagrisso in early-s...

FDA kicks off review of second kidney cancer combo based on ...

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

Ibrance trial failure dashes Pfizer’s growth hopes for the d...

Shock as FDA rejects Mesoblast's Ryoncil in paediatric graft...

FDA approves BMS' Opdivo and Yervoy combination in first-lin...

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks